Welch & Forbes LLC Sells 100 Shares of Novo Nordisk A/S (NYSE:NVO)

Welch & Forbes LLC trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,598 shares of the company’s stock after selling 100 shares during the quarter. Welch & Forbes LLC’s holdings in Novo Nordisk A/S were worth $2,234,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of NVO. Jennison Associates LLC boosted its position in Novo Nordisk A/S by 100.3% during the 3rd quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock valued at $2,129,761,000 after acquiring an additional 11,727,507 shares in the last quarter. Polen Capital Management LLC bought a new position in Novo Nordisk A/S in the third quarter worth $718,995,000. FMR LLC lifted its position in Novo Nordisk A/S by 122.7% during the third quarter. FMR LLC now owns 12,077,501 shares of the company’s stock valued at $1,098,328,000 after buying an additional 6,654,614 shares during the period. Morgan Stanley boosted its holdings in shares of Novo Nordisk A/S by 96.5% during the 3rd quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after buying an additional 4,526,199 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its stake in Novo Nordisk A/S by 91.7% during the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock worth $827,354,000 after acquiring an additional 4,350,862 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NVO traded up $2.69 during midday trading on Tuesday, reaching $127.28. The company had a trading volume of 4,166,287 shares, compared to its average volume of 4,840,792. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. The company has a market cap of $571.17 billion, a P/E ratio of 43.89, a P/E/G ratio of 1.93 and a beta of 0.43. The business has a 50-day moving average of $127.33 and a two-hundred day moving average of $113.50.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of recent research reports. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. UBS Group started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating for the company. Finally, BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.